By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Multikinase inhibitors > Avapritinib > Avapritinib Dosage
Multikinase inhibitors
https://themeditary.com/dosage-information/avapritinib-dosage-7666.html

Avapritinib Dosage

Drug Detail:Avapritinib (Avapritinib [ a-va-pri-ti-nib ])

Drug Class: Multikinase inhibitors

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Stomach Cancer

300 mg orally once a day until disease progression or unacceptable toxicity

Use: For the treatment of adults with unresectable or metastatic GIST harboring a
platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations

Renal Dose Adjustments

Mild (60 to less than 90 mL/min) to moderate (30 to less than 60 mL/min) renal impairment: No adjustment recommended.
Severe (15 to less than 30 mL/min) or end-stage (less than 15 mL/min) renal impairment: Data not available

Liver Dose Adjustments

Mild (total bilirubin less than or equal to upper limit of normal [ULN] and aspartate aminotransferase [AST] greater than ULN or total bilirubin greater than 1 to 1.5 times ULN and any AST) or moderate (total bilirubin greater than 1.5 to 3 x ULN and any AST) hepatic impairment: No adjustment recommended.
Severe hepatic impairment: Data not available

Dose Adjustments

RECOMMENDED DOSE REDUCTIONS:

  • First dose reduction: 200 mg orally once a day
  • Second dose reduction: 100 mg orally once a day
  • Permanently discontinue therapy in patients unable to tolerate 100 mg orally once a day.

RECOMMENDED DOSE REDUCTIONS FOR ADVERSE REACTIONS:
INTRACRANIAL HEMORRHAGE:
Grade 1 or 2:
  • First occurrence: Withhold this drug until resolution; resume at reduced dose.
  • Subsequent occurrence: Permanently discontinue this drug.
Grade 3 or 4:
  • Permanently discontinue this drug.
CENTRAL NERVOUS SYSTEM EFFECTS:
  • Grade 1: Continue at same dose or withhold until improvement to baseline or resolution; resume at same OR reduced dose.
  • Grade 2 or 3: Withhold this drug until improvement to baseline, Grade 1, or resolution; resume at same OR reduced dose.
Grade 4: Permanently discontinue therapy.
OTHER ADVERSE REACTIONS:
Grade 3 or 4: Withhold this drug until improvement to less than or equal to Grade 2; resume at same OR reduced dose.

Concomitant Use of Strong or Moderate CYP450 3A Inhibitors:
  • Avoid concomitant use of this drug with strong or moderate CYP450 3A inhibitors.
  • If concomitant use with a moderate CYP450 3A inhibitor cannot be avoided, reduce the starting dose of this drug from 300 mg once a day to 100 mg a day.

Precautions

CONTRAINDICATIONS:

  • None

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

  • This drug should be taken on an empty stomach, at least 1 hour before or 2 hours after a meal.
  • Do not take an additional dose if vomiting occurs after taking this drug but continue with the next scheduled dose.
  • If a dose is missed do not make up for a missed dose within 8 hours of the next
scheduled dose.

Storage requirements:
  • Store at 20C to 25C (68F to 77F); excursions are permitted from 15C to 30C (59F to 86F).
Share this Article
Latest News
Medical News

Seed oils: Omega-6 fatty acids may lower diabetes, heart disease risk

Jun 01, 2025
Type 2 diabetes: Sugary drinks may significantly raise risk
COVID-19: Who do the new vaccine guideline changes affect?
Vitamin D supplements may help slow down aging by 3 years
Aging: Exercise timing, consistency can affect heart and lung fitness
Heart health: Exercise not enough to offset effects of poor sleep
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by